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Background: In extremely premature infants, postnatal growth restriction (PNGR) is
common and increases the risk of developing bronchopulmonary dysplasia (BPD)
and pulmonary hypertension (PH). Mechanisms by which poor nutrition impacts lung
development are unknown, but alterations in the gut microbiota appear to play a role.
In a rodent model, PNGR plus hyperoxia causes BPD and PH and increases intestinal
Enterobacteriaceae, Gram-negative organisms that stimulate Toll-like receptor 4 (TLR4).
We hypothesized that intestinal dysbiosis activates intestinal TLR4 triggering systemic
inflammation which impacts lung development.
Methods: Rat pups were assigned to litters of 17 (PNGR) or 10 (normal growth) at birth
and exposed to room air or 75% oxygen for 14 days. Half of the pups were treated with
the TLR4 inhibitor TAK-242 from birth or beginning at day 3. After 14 days, pulmonary
arterial pressure was evaluated by echocardiography and hearts were examined for right
ventricular hypertrophy (RVH). Lungs and serum samples were analyzed by western
blotting and immunohistochemistry.
Results: Postnatal growth restriction + hyperoxia increased pulmonary arterial pressure
and RVH with trends toward increased plasma IL1β and decreased IκBα, the inhibitor of
NFκB, in lung tissue. Treatment with the TLR4 inhibitor attenuated PH and inflammation.
Conclusion: Postnatal growth restriction induces an increase in intestinal
Enterobacteriaceae leading to PH. Activation of the TLR4 pathway is a promising
mechanism by which intestinal dysbiosis impacts the developing lung.
Keywords: intestinal dysbiosis, TLR4, pulmonary hypertension, bronchopulmonary dysplasia, premature infant,
Enterobacteriaceae
INTRODUCTION
Pulmonary hypertension (PH) is an increase in pulmonary vascular resistance resulting in a
decrease in pulmonary blood flow and right ventricular hypertrophy (RVH). The incidence of PH
among extremely premature infants (birth weight less than 1000 g) is as high as 18% and increases
to 25–40% among premature infants with bronchopulmonary dysplasia (BPD), a chronic lung
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disease (1, 2). In this population, PH is associated with
very high morbidity and 50% mortality (3). PH is often not
diagnosed until the patient develops severe right ventricular
dysfunction. Current screening methods are unreliable, and no
early biomarkers of PH exist.
A large cohort study found that 79% of premature infants
with gestational age<27 weeks displayed poor growth after birth
(post-natal growth restriction, PNGR) (4). PNGR is associated
with a sustained elevation in C-reactive protein (5) and increases
the risk of PH, BPD and other diseases of prematurity including
necrotizing enterocolitis (NEC), an inflammatory disease of the
intestines (6–8). In a recent prospective study of PH, among
extremely preterm infants with BPD (mean gestational age at
birth 26 weeks) evaluated at 36 to 38 weeks corrected gestational
age, 13/44 (30%) patients with PH had a history of NEC, while
only 8/115 (7%) patients without PH had a history of NEC
[adjusted odds ratio 5.5 (95% confidence intervals 1.9, 15.4)] (9),
suggesting an association between inflammation in the gut and
pulmonary vascular disease. A meta-analysis confirmed a strong
association between NEC and PH particularly among infants with
BPD (RR 3.4 with 95% confidence intervals 1.1 and 10.2) (10).
Similar to preterm infants, rats are born in the saccular
stage of lung development. Neonatal rats exposed to hyperoxia
(75–95% O2) for 14 days develop PH, RVH, pulmonary vascular
remodeling, and alveolar simplification characteristic of preterm
infants with BPD (11). We have shown in a novel rodent model
that PNGR, achieved by increasing litter size from 10 to 17
pups, triggers PH and amplifies the adverse effects of hyperoxia
at 2 weeks of age (12, 13). This age is roughly equivalent to a
human infant at 6–12 months (14), a common time of death for
premature infants with PH.
Associations between nutrition, the intestinal microbiota
and immune responses in distant sites such as the lung,
brain and liver have prompted study of the gut-lung, gut-
brain, and gut-liver axes. We recently reported that PNGR,
but not hyperoxia, alters the intestinal microbiota in rats
at 14 days (15). Partially correcting the dysbiosis with a
probiotic strain of Lactobacillus reuteri attenuates PNGR-induced
PH (15). We also reported an increase in pro-inflammatory
Gram-negative Enterobacteriaceae in the distal small bowel
of rat pups exposed to both PNGR and hyperoxia (15).
Recognition of lipopolysaccharide (LPS) in the cell wall of
Enterobacteriaceae by the host Toll-like receptor (TLR)4 is
important in the pathogenesis of NEC, and both inhibition
of TLR4 and manipulation of the intestinal microbiota with
probiotic organisms prevents this disease (16, 17). TLR4 signaling
is also important in lung injury and inflammation (18). In a
rodent model of NEC, lung injury is prominent and can be
attenuated by deletion of TLR4 from the pulmonary epithelium
(19). Furthermore, activation of TLR4 in the NEC model
induced expression of chemokine ligand 25 (CC25) resulting
in recruitment of Th17 cells to the lungs (20). From these
studies we hypothesized that TLR4 –induced inflammation in
the intestines is an important mechanism by which PNGR-
associated dysbiosis triggers PH in rat pups. The goal of this
study was to investigate the role of TLR4 in the developing
gut-lung axis.
MATERIALS AND METHODS
Animals
The animal protocol was approved by the Institutional Animal
Care and Use Committee at UC Davis. Timed-pregnant Sprague
Dawley dams at E14-E16 were ordered from Charles River
Laboratories (Wilmington, MA, United States). Rats were housed
in plastic cages with a 12 h dark:light cycle and allowed to feed
ad libitum with a standard diet (2018 Teklad from Harlan). After
birth, pups were pooled and randomly assigned to litters of 10
pups (normal litter size, N) or 17 pups (restricted litter size, R).
Additionally, pups were randomly assigned to cages maintained
in room air (A) or exposed to 75% oxygen (O) in a plexiglass
chamber (Biospherix, Lacona, NY, United States) continuously,
and dams were rotated with the appropriate control or PNGR
dam every 24 h. As we have shown previously, the pups tolerate
hyperoxia for 14 days without mortality (12). Some pups in
each group were injected subcutaneously with the TLR4 inhibitor
TAK-242 (Cayman Chemicals, Ann Arbor, MI, United States)
(Resatorvid, 3 mg/kg/day from birth) or with vehicle alone (5%
ethanol). The dose was chosen based on a previous study in a
mouse sepsis model (21). At postnatal day 14, the pups were
analyzed by echocardiography, weighed and euthanized for tissue
harvest. Pups were euthanized by exposure to CO2 followed by
cardiac puncture and exsanguination, and plasma was collected
by centrifugation in heparin-treated tubes (Thermo Fisher
Scientific) and stored at −80◦C. Hearts and lungs, were snap-
frozen in liquid nitrogen and stored at −80◦C. The intestinal
microbiota was not evaluated for this series of experiments, but
has previously been reported for this model (15).
Echocardiography
At day 14, echocardiography was performed on pups under light
anesthesia with isoflurane using a VisualSonics VIVO 2100 in
vivo ultrasound imaging system (VisualSonics, Toronto, ON,
Canada) to determine the ratio of the pulmonary acceleration
time (PAT) to the total ejection time (ET) a marker of PH as
previously described (12).
Measurement of Right Ventricular
Hypertrophy (RVH)
Fulton’s index [the weight of the right ventricle (RV) divided by
the weight of the left ventricle (LV) + septum] was determined
to assess RVH. Additionally, RV and LV + septum weights were
normalized to body weight (22).
Plasma IL-1b was quantified using the Rat IL-1 beta
Platinum ELISA kit (Thermo Fisher Scientific, Waltham, MA,
United States) according to the manufacturer’s instructions.
Western blots were performed on lung tissue as previously
described (12). Briefly, lung tissue was suspended in RIPA buffer
containing protease and phosphatase inhibitors and sonicated
on ice. Protein content was determined by the Bradford method
and Western blotting performed using 1:500 dilution of mouse
anti-IκB-α antibody (sc-1643, Santa Cruz Biotechnology, Dallas,
TX, United States) at 4◦C overnight followed by a 60 min
incubation with an anti-mouse secondary antibody conjugated to
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horseradish peroxidase (Santa Cruz). Blots were then probed for
β-actin (ab6276, 1:4000, Abcam, Cambridge, MA, United States)
for 60 min at room temperature. Chemiluminescence generated
by Super Signal West Femto substrate (Thermo Fisher Scientific)
was detected and quantified using a Kodak Image Station and
software. Signals were normalized to β-actin and expressed as fold
change relative to OR animals.
Statistical Analysis
Data are presented as means ± SEM. “N” represents the number
of animals in each group. Groups were compared with one-way
ANOVA (Stata 12.1, College Station, TX, United States). If the F
test was significant, a Scheffe post hoc test was performed.
The independent variables were considered significant
at p< 0.05.
RESULTS
Our previous study identified an increase in Enterobacteriaceae
in the distal small bowel of rat pups exposed to PNGR
and hyperoxia (15). To determine if activation of TLR4 by
Enterobacteriaceae is involved in the development of PH in these
rats, we first determined the efficacy of the TLR4 antagonist
TAK-242 to attenuate PH. Increased pulmonary artery pressure
results in RVH. As we have shown previously (12), PNGR and
hyperoxia alone increase Fulton’s index (the ratio of RV weight
to LV + septum weight) with a further increase in Fulton’s
index when both are combined (Figure 1A). Daily treatment
with TAK-242 attenuated RVH in pups exposed to PNGR with
and without hyperoxia, but not in pups exposed to hyperoxia
alone (Figure 1A).
The ratio of the PAT to total ejection time (PAT/ET) detected
by echocardiography decreases with increased pulmonary artery
pressures. As we have shown previously (12), PAT/ET ratios
were significantly decreased in pups exposed to PNGR or
hyperoxia alone, and were decreased further in pups exposed
to both (Figure 1B). Daily treatment with TAK-242 attenuated
the decrease in PAT/ET ratios in pups exposed to hyperoxia
with PNGR, but not in pups exposed to PNGR or hyperoxia
alone (Figure 1B).
We opted to focus the remaining experiments on the PNGR
and hyperoxia group for four reasons: (1) we have previously
demonstrated that intestinal dysbiosis is most severe in the
PNGR and hyperoxia group with the largest increases in
Enterobacteriaceae, (2) this group consistently has the most
severe phenotype in our model, (3) this group had a significant
attenuation of both RVH and PAT/ET ratio, with TLR4 inhibition
and (4) this group most closely reflects extremely premature
infants at the highest risk for PH (those with BPD and poor
postnatal growth). We next looked at circulating levels of the
cytokine IL-1β, a downstream component of TLR4-induced
inflammatory responses. A strong trend toward higher plasma
levels was seen in pups exposed to PNGR and hyperoxia relative
to controls, while daily treatment with TAK-242 trended toward
decreased circulating IL-1β (Figure 2).
FIGURE 1 | (A) Fulton’s index (right ventricular weight divided by the
combined weight of the left ventricle and the intraventricular septum) in the
four groups of the PNGR model with and without treatment with the TLR4
inhibitor TAK-242. One way ANOVA p < 0.001, AN vs. AR p = 0.2, AN vs. ON
p = 0.01, AN vs. OR p < 0.001, OR vs. OR + TAK242 p = 0.04 (Scheffe).
Comparing just the AN vs. AR (not considering the other groups), using a
t-test, p < 0.001. Number of animals AN = 21, AN + TAK242 = 5, AR = 16,
AR + TAK242 = 17, ON = 20, ON + TAK242 = 14, OR = 17,
OR + TAK242 = 15. (B) Ratio of PAT to total ejection time (PAT/ET) in the four
groups of the PNGR model with and without treatment with the TLR4 inhibitor
TAK-242. One way ANOVA p < 0.001, AN vs. AR p < 0.001, AN vs. ON
p < 0.001, AN vs. OR p < 0.001, OR vs. OR + TAK242 p = 0.18 (Scheffe).
Comparing just the OR vs. OR + TAK242 (not considering the other groups),
using a t-test, p < 0.001. Number of animals AN = 25, AN + TAK242 = 5,
AR = 19, ARTAK242 = 17, ON = 20, ON + TAK242 = 15, OR = 16,
OR + TAK242 = 17. Asterisks in both A and B are from the Scheffe post hoc
test: ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. AN = room air, normal litter size;
AR = room air, growth-restricted litter size; ON = hyperoxia, normal litter size;
OR = hyperoxia, growth-restricted litter size.
FIGURE 2 | Plasma IL-1β measured by ELISA at day 14 in pups from the air,
normal litter size group and the hyperoxia, PNGR group with and without
treatment with the TLR4 inhibitor TAK-242. One way ANOVA p = 0.046, AN
vs. OR p = 0.08 and OR vs. OR + TAK242 p = 0.12 (Scheffe). Number of
animals: AN = 8, OR = 8, OR + TAK242 = 5.
We quantified levels of IκBα protein in lung as a marker
of lung inflammation. IκBα is an inhibitory protein of the key
pro-inflammatory transcription factor NFκB, and decreases in
Frontiers in Immunology | www.frontiersin.org 3 March 2020 | Volume 11 | Article 357
fimmu-11-00357 March 3, 2020 Time: 19:27 # 4
Wedgwood et al. TLR4 and the Gut-Lung Axis
IκBα indicate an increase in NFκB-mediated inflammation. IκBα
protein trended to a decrease in lungs from rats exposed to PNGR
and hyperoxia relative to controls, while daily treatment with
TAK-242 significantly increased IκBα levels (Figure 3).
In our proposed pathway, intestinal dysbiosis precedes and
initiates TLR4 signaling. This raises the possibility that delayed
treatment, either to alter the intestinal microbiota or to inhibit
TLR4 targeting may be effective in attenuating PH, an advantage
in the management of a disease that is not apparent in the
premature infant in the first days and weeks of life. To test this
hypothesis, we performed additional experiments in which the
pups were divided into the four groups on day 1 as usual, but the
intervention was not begun until day of life 3. Delaying treatment
with TAK-242 until postnatal day 3 still led to significantly
increased PAT/ET on day 14 in pups exposed to PNGR and
hyperoxia (Figure 4) indicating attenuated PH.
DISCUSSION
Postnatal growth restriction is common with very premature
birth and increases the risk of BPD and PH. Retrospective
cohort studies have demonstrated associations between decreased
caloric intake in the first weeks of life and BPD in very preterm
FIGURE 3 | Lung IκBα measured by western blotting at 14 days in pups from
the air, normal litter size group and the hyperoxia, PNGR group with and
without treatment with the TLR4 inhibitor TAK-242. (A) Representative blot
(B). Each band was normalized to β-actin and to OR (each point represents a
fold change compared to the mean OR value) One way ANOVA p < 0.01, AN
vs. OR p = 0.11 and OR vs. OR + TAK-242 p < 0.02 (∗Scheffe). Number of
animals: AN = 11, OR = 19, OR + TAK242 = 9.
FIGURE 4 | Ratio of pulmonary acceleration time to total ejection time
(PAT/ET) in pups exposed to hyperoxia and PNGR model with and without
delayed treatment (day 3) with the TLR4 inhibitor TAK-242. ∗∗p < 0.01.
Number of animals: OR = 16, OR + delayed TAK242 = 6.
infants (6, 7, 23), and limited studies of aggressive nutrition in
the first weeks of life have shown benefit in decreasing BPD in
this same population (24). NEC is also a risk factor for PH in very
preterm infants both with and without BPD (9), supporting the
hypothesis that inflammation in the gut impacts the developing
lung vasculature.
Many rodent models of PH involve exposing neonatal pups to
hyperoxia, although our model including a component of PNGR
more closely approximates clinical conditions in extremely
premature infants. As such it is a powerful tool to investigate the
underlying mechanisms whereby the most vulnerable extremely
low birth weight premature infants (those with poor growth
receiving supplemental oxygen) are at greatest risk of developing
cardiovascular diseases. From these data and our previously
published study (15) we hypothesized that PNGR combined
with hyperoxia triggers intestinal dysbiosis including elevated
Enterobacteriaceae. Blooms of Enterobacteriaceae have been
identified just prior to the onset of necrotizing enterocolitis in
premature infants (25) and are a signature of dysbiosis in many
disease processes (26). We further hypothesized that the resultant
activation of TLR4 by Enterobacteriaceae in the intestines triggers
an inflammatory response including elevated circulating IL-1β.
This transduces the inflammatory signal to the lungs activating
NFκB, leading to PH and RVH (Figure 5). The present study
identifying a role for TLR4 signaling in PH induced by PNGR and
hyperoxia supports this hypothesis. We previously demonstrated
that the probiotic L. reuteri DSM 17938 reverses dysbiosis and
attenuates PH and RVH (15), and inhibiting TLR4 signaling
likewise attenuates PH and RVH as we show here.
Furthermore, our data suggest that delayed targeting of TLR4
signaling is still effective in attenuating PH. We do not yet know
the windows of benefit for either probiotic administration or
TLR4 inhibition for successful attenuation of PH in our model,
but a potential treatment strategy for preterm infants may involve
early probiotic treatment with subsequent targeting of TLR4
signaling in high risk infants.
Studies investigating the gut-lung axis have prompted the
hypothesis that intestinal dysbiosis is an important driver of
systemic inflammation (27). These associations are particularly
important in preterm neonates with immature gut and lung
immune responses. Studies of human milk are particularly
relevant in this population. Human milk feeding decreases the
risk of NEC (28). Meta-analyses suggest a benefit in feeding
mother’s own milk (29) and pasteurized donor human milk (30)
in the prevention of BPD. In organoids derived from the terminal
ileum of mouse pups, human milk exosomes have been shown
to attenuate LPS induced activation of TLR4 (31). Human milk
oligosaccharides interact with TLR4 on the surface of dendritic
cells inducing immune tolerance through increased generation
of regulatory T cells and attenuation of LPS-induced expression
of IL6 and TNFα (32). It is also possible that TLR4 is important
in maintenance of stem cells in the developing gut and lung. In
the developing intestinal tract, intestinal stem cells express TLR4
which regulates proliferation and apoptosis (33). In a lung injury
model, deletion of TLR4 impairs the renewal capacity of lung
stem cells (34). Conversely, in a model of neonatal PH triggered
by intra-amniotic injection of PBS, human mesenchymal stem
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FIGURE 5 | Hypothesized role of dysbiosis and TLR4 signaling in the developing gut-lung axis.
cells decrease expression of TLR4, NFκB, and TNFα in the heart
and attenuate PH (35).
Toll-like receptors are important in recognition of pathogen-
associated molecular patterns and triggering of innate immune
responses in both the gut and the lung, as demonstrated in the
studies of TLR4 in NEC-associated lung injury noted in the
introduction. TLR4 activates IL-1β transcription via NFκB (36).
The role of TLR4 in regulating pulmonary vasculogenesis has also
been explored. Adult TLR4-deficient mice do not develop PH
when exposed to hypoxia (37). Stimulation of TLR4 on platelets
leads to platelet activation and aggregation exacerbating PH (and
as a result selective knockout of TLR4 on platelets is protective)
(38). The increase in Enterobacteriaceae in our PNGR model
suggests a potential role for TLR4 in the intestine and/or the
lung in the resultant PH. Probiotic microbes impact host immune
responses including downregulation of TLR4 (39), chemokines
and cytokines (40–46), suppression of T-helper 2 responses
(47) decrease in intestinal permeability (48–51), alteration of
intestinal motility (52, 53), and production of short chain fatty
acids (54, 55).
Lung inflammation is involved in the development of PH in
humans and animal models (56). We believe the current study
is the first to demonstrate a potential role for an inflammatory
response initiating in the intestines in PNGR/hyperoxia-induced
PH. Our studies do not rule out the possibility of a TLR4 response
induced in the lung following simultaneous exposure to PNGR
and hyperoxia; direct measurement of TLR4 in both the gut and
lung would be valuable to address this possibility. Activation
of lung TLR4 using aerosolized LPS results in elevated IL-1β
in bronchiolar lavage fluid in mice (57), while treatment with
the anti-inflammatory molecule dioscin suppresses various pro-
inflammatory molecules including TLR4, IL-1β and NFκB in the
lungs of rats injected with LPS (58). Our current study indicated
that subcutaneous TAK-242 is effective at attenuating PH in
our model. Further studies comparing the efficacy of TAK-242
delivered intranasally or via gavage may identify where TLR4 is
activated in rats exposed to PNGR and hyperoxia. Measurement
of IL1β in both intestinal and lung tissue in this model would be
of value in future studies.
In the current study we demonstrate that IκBα levels
were decreased in the lungs of rats exposed to PNGR and
hyperoxia, while TAK-242 prevented this decrease. Increased
NFκB activity is evident in explanted lungs of patients with
idiopathic PH (59), and an NFκB decoy delivery into lungs
prevents monocrotaline-induced NFκB activity and PH in rats
(59) suggesting that elevated lung NFκB activity plays a central
role in the pathogenesis of PH. We have previously shown a
decrease in IκB in the lungs and pulmonary arteries in a lamb
model of persistent PH of the newborn suggesting a potential
role for NFκB-target genes in pulmonary vascular remodeling
(60). Direct measurement of NFκB in lung tissue in this model
would be of value.
In summary, we show that TLR4 inhibition attenuated PH,
RVH, and decreased lung IκBα activity in rat pups exposed
to PNGR and hyperoxia with a trend toward decreasing
elevated circulating IL-1β. Further elucidation of the underlying
mechanisms may identify crucial spatial (intestinal and
pulmonary) and temporal targets to improve clinical outcomes
of low birth weight preterm infants at risk of developing PH.
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